Antisense inhibition of survivin expression as a cancer therapeutic.
about
Targeting caspases in cancer therapeuticsAurora B hyperactivation by Bub1 overexpression promotes chromosome missegregationExpanding the number of 'druggable' targets: non-enzymes and protein-protein interactionsSplice isoforms as therapeutic targets for colorectal cancerPotential molecular targeting of splice variants for cancer treatmentNuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.BPIQ, a novel synthetic quinoline derivative, inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft modelLoss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinomaAssessment of mRNA splice variants by qRT-PCR.Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.Antisense oligonucleotide targeting matrix metalloproteinase-7 (MMP-7) changes the ultrastructure of human A549 lung adenocarcinoma cells.Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma.Targeting survivin in cancer: novel drug development approaches.Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery systemTargeting survivin overcomes drug resistance in acute lymphoblastic leukemia.Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastomaTheranostic properties of a survivin-directed molecular beacon in human melanoma cells.Correction of microtubule-kinetochore attachment errors: mechanisms and role in tumor suppression.Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft ModelsCell death signaling and anticancer therapyPrognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cellDentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition.Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cellsDelivery of a survivin promoter-driven antisense survivin-expressing plasmid DNA as a cancer therapeutic: a proof-of-concept studyHoly Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy.Survivin promotion of melanoma metastasis requires upregulation of α5 integrinOncogenic alternative splicing switches: role in cancer progression and prospects for therapy.Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.Survivin in solid tumors: rationale for development of inhibitors.Survivin signaling in clinical oncology: a multifaceted dragon.Prognostic value of survivin expression in breast cancer patients: a meta-analysis.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Monitoring survivin expression in cancer: implications for prognosis and therapy.Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective.Effect of Terminal Groups of Dendrimers in the Complexation with Antisense Oligonucleotides and Cell Uptake.Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo.ROS-mediated activation of JNK/p38 contributes partially to the pro-apoptotic effect of ajoene on cells of lung adenocarcinoma.The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.
P2860
Q26821986-40F3F146-37EC-4BDC-89B6-4B40B325AC30Q26995347-A379957D-5249-4598-8644-E4663574172CQ27003966-49CC0A23-E26A-47E2-BF05-A60BB14F4ECFQ27006500-CE6DB290-7567-44F3-85D0-84D6EE92F476Q27008529-B41A4F23-5BBF-43E4-849F-90BDD8B8BD74Q27853025-E33BD926-BB80-4E61-B5C1-6C6D10AC798FQ28396577-7480B926-4A58-4265-8B10-934E85865E20Q28535017-34D569D5-F761-45CE-90FA-8ED415A21E55Q33765915-A4A78FF9-5480-47C3-931A-EE39E8B0504CQ33809839-C7881F7F-572F-47A7-B4C3-4017B1C2F057Q34043854-F5C46299-8355-42D6-8A40-E383FA77A525Q34206206-EF2700CE-466A-4A16-A7FB-AD64B978E440Q34596689-D07551E0-42A3-4FD9-8594-4BD60C7E9C58Q34954296-250E3FD6-E739-4A45-8283-02AA48A69B20Q34995488-3FF9A016-26B2-4433-96F4-65BD0CFC77D5Q35182716-A4193F9E-E0A5-4FBD-8C89-A8B12F6EBFB3Q35205627-F8B7B58C-1C75-4F34-8E38-003A3E44B7DFQ35515042-CB3CAEE4-1B3B-4409-A697-803710870A46Q35632434-9EC4F194-DCF8-4930-A325-806CFA64DCE4Q35694238-F1FCAF23-EACE-4346-94BE-3D8AD0ADDBFDQ35972102-83F0E52C-49C7-47A9-B476-BF3E7625A048Q36107064-A5E8D0E8-17B4-4629-891C-A5B475DB01F3Q36214450-FB57547A-5E94-47F1-AD30-03F2641DEA57Q36317900-39447F53-C37F-456D-BC8E-3FF320027555Q36717205-B725DB31-0863-47AC-A3FE-2C2D4778FF6AQ36887543-11E6C219-FC65-4756-8B80-B5F2AFEA96FAQ36980219-09630FF2-81DC-4CFF-BA5F-16F138E998C2Q37151634-6BDE51BA-259A-4832-951C-0BC188B75343Q37304724-73DAA673-E28B-47D2-BB02-0DE750C060CBQ37875078-660DB98F-16D5-4490-A478-074F2DFC3F79Q37974867-E422EBD4-0B24-47B5-87A2-14B1369AE1C8Q38017923-3ECAEB78-49C3-482B-AD99-2B1431894809Q38108262-E79F4479-A007-4BE9-B35D-E2A99BADE2D6Q38115574-FE0413A0-0C8D-47D2-860D-E9E50C899F3FQ38126394-1A000119-B1B9-40B7-BD40-22D994F3CF4BQ38212609-64AC4C63-5A19-4DC5-B3A8-EC7713DD4131Q38264255-DC5801CE-C8F6-46A1-98ED-F1125A208247Q38695511-6C5B1168-7DDF-43C9-BF1C-0D06FADD4E47Q38827851-4B3CB3AF-0647-44D4-9BFE-6A93D40E082FQ38970758-8BF03FBE-4C02-4D1E-9408-39E19433E0EF
P2860
Antisense inhibition of survivin expression as a cancer therapeutic.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antisense inhibition of survivin expression as a cancer therapeutic.
@en
Antisense inhibition of survivin expression as a cancer therapeutic.
@nl
type
label
Antisense inhibition of survivin expression as a cancer therapeutic.
@en
Antisense inhibition of survivin expression as a cancer therapeutic.
@nl
prefLabel
Antisense inhibition of survivin expression as a cancer therapeutic.
@en
Antisense inhibition of survivin expression as a cancer therapeutic.
@nl
P2093
P1476
Antisense inhibition of survivin expression as a cancer therapeutic.
@en
P2093
Bharvin K R Patel
Eric Marcusson
George Sandusky
Nancy B Stamm
Philip Iversen
Rosa A Carrasco
P304
P356
10.1158/1535-7163.MCT-10-0756
P577
2011-01-07T00:00:00Z